Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRGN-3005 UltraCAR-T cells · 1 trial · 34 indications
Toxicity grading will be evaluated according to the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events version 5.0 and monitoring of adverse events
Will be determined by a 3 X 3 dose escalation study for both intraperitoneal infusion and intravenous infusion of the trial.
| Arm | Type | Description |
|---|---|---|
| Treatment (PRGN-3005 UltraCAR-T cells) IP Administration | EXPERIMENTAL | Patients receive autologous PRGN-3005 UltraCAR-T cells via IP administration with or without lymphodepleting chemotherapy. |
| Treatment (PRGN-3005 UltraCAR-T cells) IV Administration | EXPERIMENTAL | Patients receive autologous PRGN-3005 UltraCAR-T cells via IV administration with or without lymphodepleting chemotherapy. |
| Name | Type | Description |
|---|---|---|
| PRGN-3005 UltraCAR-T cells | BIOLOGICAL | Given IP |
Inclusion Criteria: * Women with recurrent, advanced, platinum resistant ovarian, fallopian tube, and primary peritoneal cancer that have progressed after receiving standard of care therapies or are not eligible to receive available therapies with known clinical benefit will be eligible for the stu...
PRGN-3005 UltraCAR-T cells is an investigational cell therapy being studied for the treatment of platinum-resistant fallopian tube carcinoma, as well as platinum-resistant ovarian and primary peritoneal cancers. It is currently in Phase 1 clinical development and is not yet approved by the FDA.
PRGN-3005 UltraCAR-T cells is being developed by Precigen, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol PGEN. The company is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of this investigational therapy in patients with advanced, recurrent platinum-resistant gynecologic cancers.
PRGN-3005 UltraCAR-T cells is in Phase 1 clinical development. The ongoing trial is active but not recruiting participants, and it is designed to evaluate the investigational therapy in patients with platinum-resistant fallopian tube, ovarian, and primary peritoneal cancers. The therapy has not received FDA approval.
PRGN-3005 UltraCAR-T cells is being evaluated in a single Phase 1 clinical trial with the identifier NCT03907527. This study is enrolling female patients aged 18 years and older with advanced, recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The trial is active but not recruiting and has a target enrollment of 71 participants.
PRGN-3005 UltraCAR-T cells is not FDA approved. It is an investigational cell therapy currently in Phase 1 clinical development. The therapy is being studied for the treatment of platinum-resistant fallopian tube carcinoma and related gynecologic cancers, but it has not yet received regulatory approval for any indication.